Y-mAbs CFO Bo Kruse resigns, search for successor begins
YMAB Stock | USD 8.17 0.20 2.51% |
About 56% of all Y MAbs' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that some traders are interested. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs CFO Bo Kruse resigns, search for successor begins
Read at investing.com
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Y MAbs is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
PASG | Passage Bio | 45.61 | ||||
ZNTL | Zentalis Pharmaceuticals | 8.00 | ||||
CCCC | C4 Therapeutics | 7.10 | ||||
BLUE | Bluebird Bio | 5.64 | ||||
LRMR | Larimar Therapeutics | 4.24 | ||||
GBIO | Generation Bio | 3.60 | ||||
KRON | Kronos Bio | 3.09 | ||||
BDTX | Black Diamond | 2.80 | ||||
EWTX | Edgewise Therapeutics | 2.55 | ||||
SNDX | Syndax Pharmaceuticals | 2.06 | ||||
MRUS | Merus BV | 2.03 | ||||
PCVX | Vaxcyte | 1.87 | ||||
MIRM | Mirum Pharmaceuticals | 1.81 | ||||
ERAS | Erasca | 1.48 | ||||
STRO | Sutro Biopharma | 1.04 | ||||
ARQT | Arcutis Biotherapeutics | 0.41 | ||||
RVMD | Revolution Medicines | 0.27 | ||||
TVTX | Travere Therapeutics | 0.58 | ||||
MRSN | Mersana Therapeutics | 0.71 | ||||
DAWN | Day One | 0.94 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |